APP and Alzheimer disease: Future optimization of oral or injectable formulations, combined with systematic validation of spatial memory, cognitive function, and peripheral safety metrics in AD mouse models (e.g., APP/PS1, 5× FAD), could accelerate its translation to clinical applications.